In addition to their effects on type 2 diabetes, weight loss and colorectal cancer risk, glucagon-like peptide-1 receptor analogues may also act on nine other obesity-related cancers, reports a new study.
Much of the focus for proactive treatments for patients with diabetes has been on type 2 diabetes. But what can be done for patients at risk of developing type 1 diabetes?
Canadian company Sandoz is set to launch the very first generic semaglutide in 2026, making this costly treatment more accessible, possibly raising other issues.
Stigma, feelings of shame and even discrimination continue to be commonplace among people with both type 1 and type 2 diabetes, according to the findings of a new survey.
The shift in recognizing obesity as a chronic disease, rather than simply a lifestyle issue, has elevated the importance of its management within healthcare. Pharmacists are excited because this change aligns with their focus on chronic disease management and provides new opportunities to address obesity with the same seriousness as diabetes or hypertension.
